IPW

OIPE IAP85 FEB 02 2006 PATENT & TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lawrence E. Fosdick et al.
Application No. 10/685,125
Filed: October 13, 2003
Confirmation No. 4540
For: GLUCOSAMINE AND METHOD OF MAKING GLUCOSAMINE FROM MICROBIAL BIOMASS
Examiner: Shengjun Wang
Art Unit: 1617
Attorney Reference No. 6682-65310-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s) _____

Date Mailed January 30, 2006

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this Information Disclosure Statement is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By _____
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

cc: Docketing

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

OIPE IAP85 FEB 02 2006 PATENT & TRADEMARK OFFICE

Attorney Docket Number	6682-65310-01
Application Number	10/685,125
Filing Date	October 13, 2003
First Named Inventor	Fosdick
Art Unit	1617
Examiner Name	Shengjun Wang

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		2003/0134825	07/17/2003	Bahoshy
		2003/0138543	07/24/2003	Bahoshy
		2003/0170374	9/11/2003	Bahoshy
		2002/0160459	10/31/2002	Berry et al.
		6,225,493	5/1/2001	Prakash et al.
		6,432,929	8/13/2002	Stone

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 01/93847 A2, A3	13.12.2001	The Procter & Gamble Company
		WIPO	WO 03/013435 A2	20.02.2003	Cargill, Incorporated

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		Database Caplus on STN: Accession No. 1976-519336 (1976).
		Database Caplus on STN: Accession No. 1999:816485 (1999).
		Domanski et al., "Use of a Chitinase Complex and β-(1,3)-Glucanase for Spheroplast Production from *Candida albicans*," *J. Bacteriol. 96*:270-271 (1968).

EXAMINER SIGNATURE:	DATE CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.